From: Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Name of mAb | Commercial Name | Approval Year | Target Kinase | Mechanism of resistance |
---|---|---|---|---|
Bevacizumab (Genentech/Roche) | Avastin | 2004 | VEGFR | 4 |
Cetuximab (ImClone and Bristol-Myers Squibb) | Erbitux | 2004 | EGFR | 1,2,3,4 |
Panitumumab (Amgen) | Vectibix | 2006 | EGFR | Â |
Trastuzumab (Genentech) | Herceptin | 1998 | ERBB2 | 2,4,5 |
IMC-A12 Cixutumumab (ImClone) | Â | Phase II | IGF1-R | Â |
AVE1642 (Sanofi-Aventis) | Â | Phase I | IGF1-R | Â |
Pertuzumab (Genentech) | Omnitarg | Phase III | ERBB2 | Â |
MetMAb (Genentech) | Â | Phase I/II | MET | Â |
IMC-1121B Ramucirumab (ImClone) | Â | Phase III | VEGFR-2 | Â |
IMC-18F1 (ImClone) | Â | Phase I | VEGFR | Â |
AMG-102 Rilotumumab (Amgen) | Â | Phase II | MET | Â |